Refile: BUZZ-Tracon Pharma up on FDA fast track designation for cancer drug

TRACON Pharmaceuticals

14/09/2022 13:57

(Corrects typo in headline)
    ** Drug developer Tracon Pharmaceuticals Inc's  TCON.O 
shares rise 2.6% to $1.95 before the bell
    ** Co says U.S. FDA grants fast track designation for its
experimental drug, Envafolimab, to treat cancer of soft tissues
 urn:newsml:reuters.com:*:nGNX3sNYkz
    ** Fast track designation confers priority review, when
marketing application for the drug is submitted to the FDA, and
is given to drugs that treat serious or life-threatening
diseases or conditions which fill unmet medical needs
    ** Envafolimab is currently undergoing a mid-stage trail in
the U.S. to treat patients with cancer of soft tissue
    ** Up to Tuesday's close, stock had lost ~31% YTD 

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))